Pharmacokinetics and short-term efficacy of a double-boosted protease inhibitor regimen in treatment-naive HIV-1-infected adults
J van der Lugt, RS Autar, S Ubolyam… - Journal of …, 2008 - academic.oup.com
Objectives To study the pharmacokinetics and short-term efficacy of low and standard dose
lopinavir/ritonavir and saquinavir combinations in Thai, human immunodeficiency virus (HIV) …
lopinavir/ritonavir and saquinavir combinations in Thai, human immunodeficiency virus (HIV) …
Steady-state pharmacokinetics of a double-boosting regimen of saquinavir soft gel plus lopinavir plus minidose ritonavir in human immunodeficiency virus-infected …
E Ribera, RM Lopez, M Diaz, L Pou… - Antimicrobial agents …, 2004 - Am Soc Microbiol
Management of treatment-experienced human immunodeficiency virus patients has become
complex, and therapy may need to include two protease inhibitors at therapeutic doses. The …
complex, and therapy may need to include two protease inhibitors at therapeutic doses. The …
Exploratory study comparing the metabolic toxicities of a lopinavir/ritonavir plus saquinavir dual protease inhibitor regimen versus a lopinavir/ritonavir plus zidovudine …
DW Cameron, S Becker, MS King… - Journal of …, 2007 - academic.oup.com
Objectives To assess the safety, efficacy and metabolic toxicity of lopinavir/ritonavir+
saquinavir or zidovudine/lamivudine and evaluate the pharmacokinetics of …
saquinavir or zidovudine/lamivudine and evaluate the pharmacokinetics of …
Ritonavir-saquinavir dual protease inhibitor compared to ritonavir alone in human immunodeficiency virus-infected patients
C Michelet, A Ruffault, V Sébille, C Arvieux… - Antimicrobial agents …, 2001 - Am Soc Microbiol
The objective of this study was to evaluate the antiretroviral efficacy and safety of ritonavir
(600 mg twice a day [bid])-saquinavir (400 mg bid) compared to ritonavir (600 mg bid) in …
(600 mg twice a day [bid])-saquinavir (400 mg bid) compared to ritonavir (600 mg bid) in …
Superior virological efficacy of ritonavir-boosted protease inhibitor regimens compared to single protease inhibitor therapy.
M Lichterfeld, A Wöhrmann, N Schmeisser… - European journal of …, 2003 - europepmc.org
Low dose-ritonavir boosted protease inhibitors are increasingly being used for the first-line
antiretroviral treatment, though their virological efficacy has just poorly been compared to …
antiretroviral treatment, though their virological efficacy has just poorly been compared to …
Atazanavir and lopinavir/ritonavir: pharmacokinetics, safety and efficacy of a promising double-boosted protease inhibitor regimen
E Ribera, C Azuaje, RM Lopez, M Diaz, M Feijoo… - Aids, 2006 - journals.lww.com
Objective: To assess the pharmacokinetics and tolerability of lopinavir (LPV), ritonavir (RTV)
and atazanavir (ATV) as a double-boosted protease inhibitor regimen in HIV-infected adults …
and atazanavir (ATV) as a double-boosted protease inhibitor regimen in HIV-infected adults …
Combination of protease inhibitors for the treatment of HIV-1-infected patients: a review of pharmacokinetics and clinical experience
RPG Van Heeswijk, AI Veldkamp, JW Mulder… - Antiviral …, 2002 - journals.sagepub.com
The use of highly active antiretroviral therapy, the combination of at least three different
antiretroviral drugs for the treatment of HIV-1 infection, has greatly improved the prognosis …
antiretroviral drugs for the treatment of HIV-1 infection, has greatly improved the prognosis …
The pharmacokinetics of HIV protease inhibitor combinations
M Boffito, D Maitland, Y Samarasinghe… - Current Opinion in …, 2005 - journals.lww.com
The pharmacokinetics of HIV protease inhibitor combinations : Current Opinion in Infectious
Diseases The pharmacokinetics of HIV protease inhibitor combinations : Current Opinion in …
Diseases The pharmacokinetics of HIV protease inhibitor combinations : Current Opinion in …
Saquinavir drug exposure is not impaired by the boosted double protease inhibitor combination of lopinavir/ritonavir
C Stephan, N v Hentig, I Kourbeti, B Dauer, M Mösch… - Aids, 2004 - journals.lww.com
Objective: To assess the pharmacokinetic interaction of saquinavir and lopinavir/ritonavir.
Design: Patients from the Frankfurt HIV cohort with limited reverse transcriptase inhibitor …
Design: Patients from the Frankfurt HIV cohort with limited reverse transcriptase inhibitor …
Predictive factors for response to a boosted dual HIV-protease inhibitor therapy with saquinavir and lopinavir in extensively pre-treated patients
N Von Hentig, E Babacan, S Staszewski… - Antiviral …, 2007 - journals.sagepub.com
Objective To evaluate predictive factors for therapy outcome of a boosted double-protease
inhibitor (PI) regimen in 58 extensively pre-treated patients with HIV. Methods Patients …
inhibitor (PI) regimen in 58 extensively pre-treated patients with HIV. Methods Patients …